Single-cell RNA sequencing analysis revealed a potential association between ELK3 expression and the progression of multiple myeloma.

This laboratory study investigated how multiple myeloma (MM), a blood cancer affecting plasma cells in bone marrow, develops and progresses through different stages. Researchers used advanced genetic sequencing technology to examine individual cells from healthy people and patients at various disease stages, from early precursor conditions to full multiple myeloma. They discovered a specific subtype of plasma cells, called C4 TTN+ cells, that becomes more prominent as the disease advances. The study also identified a protein called ELK3 that appears to help cancer cells grow, spread, and survive. Laboratory experiments confirmed that ELK3 promotes tumor cell proliferation and migration in multiple myeloma cell lines. This research is purely laboratory-based and does not involve acupuncture or integrative treatments. However, for patients undergoing conventional multiple myeloma treatment, acupuncture may offer supportive care benefits. Research has shown that acupuncture can help manage chemotherapy-related side effects including nausea, fatigue, peripheral neuropathy, and pain that commonly affect myeloma patients during treatment. Acupuncture may also support immune function and improve quality of life during cancer care. While this study advances our understanding of myeloma's cellular mechanisms and may eventually lead to new targeted therapies, it does not directly relate to acupuncture's role in cancer care. Patients interested in incorporating acupuncture alongside conventional myeloma treatment should consult with a licensed acupuncturist experienced in oncology support care.

This single-cell RNA sequencing study analyzed plasma cell heterogeneity in bone marrow samples from healthy donors and patients with MGUS, SMM, and MM obtained from the GEO database. Researchers identified a C4 TTN+ plasma cell subtype predominant in SMM and MM phases, significantly enriched during intermediate and final differentiation stages. Pseudotime analysis revealed differentiation trajectories, while CellChat and SCENIC analyses predicted that TGFβ signaling pathways mediate interactions between C4 TTN+ cells and the tumor microenvironment. In vitro validation using RPMI 8226 and U266 MM cell lines confirmed ELK3's positive regulatory effects on plasma cell proliferation, migration, and viability. The study suggests this subtype may facilitate MM progression and immune evasion. Clinical relevance: While this basic science research identifies potential therapeutic targets, acupuncture practitioners supporting myeloma patients should focus on managing treatment-related symptoms including chemotherapy-induced peripheral neuropathy, fatigue, and pain, rather than targeting disease mechanisms directly.